Canakinumab in Patients with Systemic JIA

A Dragon Claw Summary - based on a scientific paper referenced at the end.  Speak to you doctor before acting on any Dragon Claw information.

Summary

The study details safety and survival data after following JIA patients over a 5-year period. 177 patient participants were followed from 2009 to 2014 across 21 countries. Available therapies for systemic JIA include non-steroidal anti-inflammatory drugs, steroid based DMARD’s, biologic DMARDs, NTF blockers and a medication called CTL4-Ig.

Patients were encouraged to discontinue their use of glucocorticoids (Prednisone is a common example) before commencing the trial. Canakinumad is a biologic drug, a human monoclonal antibody that inhibits the inflammatory functions associated with Interleukin 1 (IL-1). Patients in the study received injections every 4 weeks. Patients who were not taking glucocorticoids did better than patients who were although a significant number could not tolerate the new biologic and discontinued. Just under half the group (40%) were doing well at the 2-year mark with pronounced reduced disease activity. Adverse side effects were few and related to increased flares and fever. Patients who were also taking glucocorticoids were able to significantly reduce or discontinue their use.

The authors conclude: “…. Response to canakinumab treatment was sustained or improved up to 5 years in patients with [systemic] JIA with active systemic features and arthritis and was associated with glucocorticoid discontinuation.”

Reference: Journal of Clinical and Epidemiological Research; 2017; Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials; Nicolina R. and Hermine B et al.